Andrew Vickers

Assessing the performance of prediction models: a framework for traditional and novel measures.

Using relative utility curves to evaluate risk prediction.

Prediction models in urology: are they any good, and how would we know anyway?

Variations among experienced surgeons in cancer control after open radical prostatectomy.

Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.

Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.

Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers.

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point.

Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.

How do you tell whether a change in surgical technique leads to a change in outcome?

Complications after radical and partial nephrectomy as a function of age.

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial.

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.

Susceptibility loci associated with prostate cancer progression and mortality.

Fellowship training as a modifier of the surgical learning curve.

Dutasteride reduces incident prostate cancer in men after negative prostate biopsy.

Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.

Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship.

Statistical consideration for clinical biomarker research in bladder cancer.

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.

Validation study of a web-based assessment of functional recovery after radical prostatectomy.

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.

Data and programming code from the studies on the learning curve for radical prostatectomy.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making.

What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?

Individual patient data meta-analysis of acupuncture for chronic pain: protocol of the Acupuncture Trialists' Collaboration.

The learning curve for laparoscopic radical prostatectomy: an international multicenter study.

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Everything you always wanted to know about evaluating prediction models (but were too afraid to ask).

Sixty years of CA: a cancer journal for clinicians.

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.

Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.

Reducing systematic review to a cut and paste.

Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.

One statistical test is sufficient for assessing new predictive markers.

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results?

Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.

A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients.

Great meaningless questions in urology: which is better, open, laparoscopic, or robotic radical prostatectomy?

Making raw data more widely available.

Tumor markers in prostate cancer I: blood-based markers.

The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience.

A safety and efficacy pilot study of acupuncture for the treatment of chronic lymphoedema.

Prediction models: revolutionary in principle, but do they do more good than harm?

Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.

Words of wisdom: Re: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.

Prediction models in cancer care.

Editorial comment.

Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures.

Screening for prostate cancer: early detection or overdetection?

How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy.

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Predicting prostate cancer many years before diagnosis: how and why?

Urological cancer: Time for another rethink on prostate cancer screening.

Risk-based prostate cancer screening.

Editorial comment.

PSA is dead, long live PSA.

We need a better marker for prostate cancer. How about renaming PSA?

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy.

Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer.

Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents.

Editorial comment.

Screening for prostate cancer.

The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial.

Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy.

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Words of wisdom. Re: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.

The trifecta: great concept, lousy statistic.

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.

Risk of cancer-specific mortality following recurrence after radical nephroureterectomy.

Acupuncture for chronic pain: individual patient data meta-analysis.

A simple decision analytic solution to the comparison of two binary diagnostic tests.

Treating metastatic disease: Which survival model is best suited for the clinic?

Radical prostatectomy versus observation for prostate cancer.

A Phase II, Randomized, Controlled Trial of Acupuncture for Reduction of Postcolectomy Ileus.

Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.

Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.

Re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87: statistical concerns with Briganti radiotherapy analysis.

Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures.

Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial.

A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons.

Four-hundredfold overestimation of biopsy mortality.

Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Responses to the Acupuncture Trialists' Collaboration individual patient data meta-analysis.

Timing of curative treatment for prostate cancer: a systematic review.

Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.

Prostate cancer: why is PSA velocity such a sticky concept?

Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.

Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.

Writing up clinical research: a statistician's view.

Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

In reply.

A personalized automated messaging system to improve adherence to prostate cancer screening: research protocol.

A systematic review of the volume-outcome relationship for radical prostatectomy.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcome.

Statistics notes: missing outcomes in randomised trials.

Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.

If something looks too good to be true, it probably is.

Evaluation of prediction models for decision-making: beyond calibration and discrimination.

Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.

Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer.

Predictors of survival in patients with disease recurrence after radical nephroureterectomy.

Characteristics of acupuncture treatment associated with outcome: an individual patient meta-analysis of 17,922 patients with chronic pain in randomised controlled trials.

What are the implications of the surgical learning curve?

Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients.

Increasing value and reducing waste: addressing inaccessible research.

It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.

Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.

Multimorbidity and evidence generation.

Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.

A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer.

Does the net reclassification improvement help us evaluate models and markers?

Acupuncture for chronic pain.

Effects of surgeon variability on oncologic and functional outcomes in a population-based setting.

Prostate cancer mortality in areas with high and low prostate cancer incidence.

Urinary cell mRNA profiles and differential diagnosis of acute kidney graft dysfunction.

Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Influence of control group on effect size in trials of acupuncture for chronic pain: a secondary analysis of an individual patient data meta-analysis.

Can we deliver randomized trials of focal therapy in prostate cancer?

Reply: To PMID 24824406.

Counseling the post-radical prostatectomy patients about functional recovery: high predictiveness of current status.

How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through.

Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Copy number alteration burden predicts prostate cancer relapse.

Guidelines for reporting of statistics in European urology.

Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Calibration of risk prediction models: impact on decision-analytic performance.

Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

European urology: serving our readership through systematic peer review, use of reporting standards, and encouragement of postpublication review.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

A simple schema for informed decision making about prostate cancer screening.

Defining a standard set of patient-centered outcomes for men with localized prostate cancer.

Clinical trials in crisis: Four simple methodologic fixes.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation.

Response from the author.

WITHDRAWN: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting.

A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.

Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial.

Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.

Decision analysis of dutasteride use for patients with negative prostate biopsy.

Reply: To PMID 25623680.

The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Preoperative predictive model of recovery of urinary continence after radical prostatectomy.

Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.

Four flawed arguments against prostate-specific antigen screening (and 1 good one).

Are we ready to predict late effects? A systematic review of clinically useful prediction models.

Informed decision making about prostate cancer screening.

Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.

Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Spotlight on prostate cancer: the latest evidence and current controversies.

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

The Lake Wobegon Effect: Why Most Patients Are at Below-Average Risk.

Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.

A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.

Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?

Unexpected Long-term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-reported Outcomes Following Radical Prostatectomy.

Lessons of War: Turning Data Into Decisions.

Who and when should we screen for prostate cancer? Interviews with key opinion leaders.